Peptides exhibit a wide array of functions such as governing cell to cell functions, cell transfer, hormonal functions, and others. Due to their broad range of applications, these have emerged as particular interest to scientists.
“Global Peptide Cancer Therapeutics Market, Drug Dosage, Price and Clinical Trials Insight 2026" Report highlights:
- Global cancer Peptide Market Opportunity: > US$ 20 Billion By 2026
- Price, Dosage, Sales Insight On 22 Marketed Cancer Peptides
- Global Peptide Cancer Therapeutics Clinical Trials Overview by Company, Country, Indication, Phase & Formulation
- Comprehensive Clinical Insight On More Than 150 Cancer Peptides In Clinical Trials
- Comprehensive Clinical Insight On More Than 20 Cancer Peptides Available In Market
- Application of Peptides Therapeutics & Detection Methodology by Cancer
Download Report:
Peptides exhibit a wide array of functions such as governing cell to cell functions, cell transfer, hormonal functions, and others. Due to their broad range of applications, these have emerged as particular interest to scientists. The use of peptides as clinical therapeutics is dated back with the development of first recombinant insulin for the management of diabetes. Peptides are considered as highly versatile molecules which have immense potential for the development of therapeutic agents. Earlier the peptides were used for the management of diabetes, but with the passage of time, researchers have utilized their potential in other therapeutic conditions also.
Owing to their small size and easy modifications with recombinant DNA technology, these molecules have found wider range of clinical applications, including cancer. Conventional treatment against cancer includes surgery, chemotherapy, and radiotherapy; all of which are associated with side effects which hamper the quality of life of patient. In contrast, the emergence of peptide based drugs has shown to successfully overcome these limitations and have proven to be efficient molecule in the management of wide range of cancer. Their extremely small size is associated with their high tissue permeability, and penetrability, thus enhancing the specificity and efficacy of drug. In addition, their ability to cross the blood brain barrier has also attracted scientists.
Peptides are highly adaptable molecules and hence can be used in number of ways like hormones, peptide drug conjugate, radionuclides, vaccines or as carrier for cytotoxic drug in the management of cancer. As of now, there are about 30 peptide based drugs approved for management of several cancers. Recently, the introduction of GV1001 (Riavax) in South Korea has further pushed the growth of market. GV1001 is peptide drug vaccine which is derived from human telomerase consisting of 16 amino acids and is indicated for the treatment of pancreatic cancer. Other peptide based vaccines are present in clinical trials, and are expected to enter the market during forthcoming years.
The promising response of peptide based drugs in the market has attracted several pharmaceutical giants to actively invest in this segment. The major key players in the market include Sanofi, Pfizer, Biogen, AstaZencea, Novo Nordisk, Merck, AbbVie, and several others. These pharmaceutical giants have adopted strategic allainces to expand their knowledge and new product launches in the market. For instance, PeptiDream, a Japanese biotechnology company, had declared a new peptide drug conjugate (PDC) collaboration with Swiss pharma major Novartis in June 2019. PeptiDream will use its proprietary Discovery Platform System technology to identify unique macrocyclic and constrained peptides, as PDCs against numerous targets of interest, chosen by Novartis.
The global peptide cancer drugs market is expected to surpass US$ XX Billion by 2026. Increase in prevalence of cancer worldwide and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the growth of market. Increasing demand for efficient and rapid acting therapeutics is further anticipated to grow the market. Apart from this, rising awareness among patients and healthcare professionals regarding adverse events of conventional cancer therapy are a high rendering factor for growing focus towards alternative therapeutics such as peptide based therapeutics.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366